AI assistant
Sending…
Pasithea Therapeutics Corp. — Director's Dealing 2025
Dec 1, 2025
35389_dirs_2025-12-01_aed1c739-2f54-4bc5-9b92-52d01628f9e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2025-11-28
Reporting Person: Schneiderman Daniel H (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-28 | Common Stock | A | 26667 | $0.75 | Acquired | 26667 | Direct |
More from Pasithea Therapeutics Corp.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Feb 20
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 12
Regulatory Filings
2026
Jan 30
Regulatory Filings
2026
Jan 28
Regulatory Filings
2026
Jan 26
Proxy Solicitation & Information Statement
2025
Dec 29